Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice

Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice

Limitations in efficacy and/or tolerance of currently available urate-lowering therapies (ULTs), such as oral xanthine oxidase inhibitors, uricosurics, and intravenous uricase agents contribute to the development of refractory gout. Renal excretion is the major route of uric acid elimination, but th...

Full description

Bibliographic Details
Main Authors: Kateryna Pierzynowska, Aditi Deshpande, Nadiia Mosiichuk, Robert Terkeltaub, Paulina Szczurek, Eduardo Salido, Stefan Pierzynowski, Danica Grujic
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Medicine
Subjects:
gout
CKD
urolithiasis
urate-lowering therapy
ABCG2
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.569215/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2020.569215/full

Similar Items